Related Experiment Video

Updated: Dec 23, 2025

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine
09:15

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine

Published on: February 24, 2023

3.8K

Cancer Immunotherapy with CDK7 Inhibitors

Giulia Petroni1, Lorenzo Galluzzi2

  • 1Department of Radiation Oncology, Weill Cornell Medical College, New York, NY, USA.

Trends in Cancer
|April 30, 2020
PubMed

Insights

Pharmacological cyclin-dependent kinase 7 (CDK7) inhibitors trigger anticancer immunity by destabilizing cancer cell genomes. This approach enhances immune system control over tumors, highlighting CDK7

Area of Science:

  • Oncology
  • Immunology
  • Cell Biology

Background:

  • Cyclin-dependent kinase 7 (CDK7) plays a role in cell cycle regulation.
  • Genomic instability in cancer cells can influence immune responses.
  • Targeting cell cycle proteins is an emerging strategy in cancer therapy.

Purpose of the Study:

  • To investigate the potential of pharmacological CDK7 inhibitors in evoking anticancer immunity.
  • To explore the link between genomic destabilization induced by CDK7 inhibition and immune system activation.
  • To assess the therapeutic value of aggravating genomic instability for immunological disease control.

Main Methods:

  • Administration of pharmacological CDK7 inhibitors to neoplastic cells.
  • Assessment of genomic destabilization in treated cancer cells.
  • Evaluation of the evoked anticancer immune response.

Main Results:

  • Pharmacological CDK7 inhibition successfully induced genomic destabilization in cancer cells.
  • This destabilization led to the evocation of anticancer immunity.
  • CDK7 inhibition adds to the known cell cycle regulators impacting immune function.

Conclusions:

  • CDK7 inhibitors represent a promising strategy for enhancing anticancer immunity.
  • Targeting CDK7 and inducing genomic instability can be leveraged for immunological cancer control.
  • Further research into CDK7's role in cancer immunity is warranted.
Keywords:
PD-1YKL-5-124immune checkpoint blockademicronucleismall cell lung cancertype I interferon

More Related Videos

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology07:04

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology

Published on: May 2, 2025

955
Tumor Transplantation for Assessing the Dynamics of Tumor-Infiltrating CD8+ T Cells in Mice07:36

Tumor Transplantation for Assessing the Dynamics of Tumor-Infiltrating CD8+ T Cells in Mice

Published on: June 12, 2021

7.3K

Related Concept Videos

Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
5.5K
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
1.7K
Cancer Vaccines01:30

Cancer Vaccines

Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
870
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.5K
M-Cdk Drives Transition Into Mitosis02:15

M-Cdk Drives Transition Into Mitosis

Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
6.2K
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
9.7K